DE69327128D1 - Hydroxylierte Metaboliten und Derivate von Doxazosin gegen Atherosklerose - Google Patents

Hydroxylierte Metaboliten und Derivate von Doxazosin gegen Atherosklerose

Info

Publication number
DE69327128D1
DE69327128D1 DE69327128T DE69327128T DE69327128D1 DE 69327128 D1 DE69327128 D1 DE 69327128D1 DE 69327128 T DE69327128 T DE 69327128T DE 69327128 T DE69327128 T DE 69327128T DE 69327128 D1 DE69327128 D1 DE 69327128D1
Authority
DE
Germany
Prior art keywords
doxazosin
atherosclerosis
derivatives
hydroxylated metabolites
retarding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69327128T
Other languages
English (en)
Other versions
DE69327128T2 (de
Inventor
Samuel Siu-Ming Wong
Archie Calhoun Swindell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of DE69327128D1 publication Critical patent/DE69327128D1/de
Publication of DE69327128T2 publication Critical patent/DE69327128T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
    • H01L2924/15—Details of package parts other than the semiconductor or other solid state devices to be connected
    • H01L2924/181—Encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69327128T 1992-04-01 1993-02-26 Hydroxylierte Metaboliten und Derivate von Doxazosin gegen Atherosklerose Expired - Fee Related DE69327128T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86171492A 1992-04-01 1992-04-01

Publications (2)

Publication Number Publication Date
DE69327128D1 true DE69327128D1 (de) 2000-01-05
DE69327128T2 DE69327128T2 (de) 2000-04-20

Family

ID=25336560

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69327128T Expired - Fee Related DE69327128T2 (de) 1992-04-01 1993-02-26 Hydroxylierte Metaboliten und Derivate von Doxazosin gegen Atherosklerose

Country Status (17)

Country Link
US (1) US5543411A (de)
EP (1) EP0564093B1 (de)
JP (1) JPH0624989A (de)
KR (1) KR0137927B1 (de)
AT (1) ATE187069T1 (de)
AU (1) AU660359B2 (de)
CA (1) CA2092983C (de)
DE (1) DE69327128T2 (de)
DK (1) DK0564093T3 (de)
ES (1) ES2139624T3 (de)
GR (1) GR3032373T3 (de)
HU (1) HU225113B1 (de)
IL (1) IL105141A (de)
MX (1) MX9301824A (de)
NZ (1) NZ247307A (de)
PT (1) PT564093E (de)
ZA (1) ZA932307B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
IL120303A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
IL120302A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
US20050165428A1 (en) * 2000-09-25 2005-07-28 Franco Kenneth L. Absorable surgical structure
JP2004508884A (ja) * 2000-09-25 2004-03-25 コヒージョン　テクノロジーズ，　インコーポレイテッド 再吸収可能な吻合ステントおよびプラグ
CN1826207B (zh) 2003-07-18 2010-06-16 浜松光子学株式会社 激光加工方法、激光加工装置以及加工产品

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB271997A (en) * 1926-04-16 1927-06-09 Morris Engines Coventry Ltd Improvements relating to the driving of cam or other auxiliary shafts in internal combustion engines
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
US4758569A (en) * 1987-08-26 1988-07-19 Pfizer Inc. Doxazosin as an anti-atherosclerosis agent

Also Published As

Publication number Publication date
EP0564093B1 (de) 1999-12-01
AU660359B2 (en) 1995-06-22
CA2092983A1 (en) 1993-10-02
DK0564093T3 (da) 2000-03-27
DE69327128T2 (de) 2000-04-20
KR930021203A (ko) 1993-11-22
IL105141A (en) 1998-10-30
CA2092983C (en) 1996-12-31
MX9301824A (es) 1994-02-28
JPH0624989A (ja) 1994-02-01
AU3562993A (en) 1993-10-07
HU9300947D0 (en) 1993-06-28
HU225113B1 (en) 2006-06-28
GR3032373T3 (en) 2000-04-27
ES2139624T3 (es) 2000-02-16
PT564093E (pt) 2000-04-28
NZ247307A (en) 1997-06-24
HUT65849A (en) 1994-07-28
IL105141A0 (en) 1993-07-08
EP0564093A1 (de) 1993-10-06
ATE187069T1 (de) 1999-12-15
US5543411A (en) 1996-08-06
KR0137927B1 (ko) 1998-05-15
ZA932307B (en) 1994-09-30

Similar Documents

Publication Publication Date Title
FI932937A (fi) Anordning och daertill hoerande foerfarande foer kompensering av vridmomentets rippel i en permamagnet-elmotor
NO914091D0 (no) Fremgangsmaate for fremstilling av hydroksylerte inhibitorer for hiv-reverstranskriptase
FI930970A0 (fi) Imidazolderivat med bifenylsulfonylurea- eller bifenylsulfonyluretansidokedja, foerfaranden foer framstaellning av dessa och anvaendning av dessa
FI961739A (fi) Amiinisuoloja klavulaanihapon valmistamiseksi
UY24625A1 (es) Derivados de la 4-hidroxi-piperidina
ATE77552T1 (de) Doxazosin als antiatherosklerotikum.
FI931333A (fi) Foerfarande foer framstaellning av formoterol och liknande foereningar
DE69327128D1 (de) Hydroxylierte Metaboliten und Derivate von Doxazosin gegen Atherosklerose
NO930829L (no) Fremgangsmaate for fremstilling av klavulansyresalter
FI922777A0 (fi) Laitteisto telaston telavälysten säätämiseksi
DE69122284D1 (de) 4-Hydroxytetrahydropyran-2-on Derivate nützlich als cholesterin- und lipidsenkende Agenzien
ATE197950T1 (de) Guanidylmethyl cyclohexancarbonsäure ester derivate
DK30284D0 (da) Pyrrolidiner
FI922518A0 (fi) Menetelmä farmaseuttisesti käyttökelpoisten pilokarpiinijohdannaisten valmistamiseksi
FI922519A0 (fi) Menetelmä farmaseuttisesti käyttökelpoisten pilokarpiinijohdannaisten valmistamiseksi
TR199701185A2 (xx) Sefalosporin piridinyum t�revleri.
FI934035A0 (fi) Foerfarande och anordning foer stabilisering av en paoverkningsanordningstemperatur

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee